Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06438562
Other study ID # 2023-0327
Secondary ID A074600CALS/NUTR
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 2024
Est. completion date December 2024

Study information

Verified date May 2024
Source University of Wisconsin, Madison
Contact Bryan Gannon, PhD
Phone 608-265-2026
Email bgannon@wisc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to measure how well different formulations of vitamin A (VA) are absorbed by the body when they are added to bouillon (broth) as vitamin A palmitate (VAP). Fortifying bouillon cubes with VA is one potential approach to addressing VA deficiency, which is a major public health issue in many low- and lower-income countries. The main question this study aims to answer is to compare the amount of VA that is absorbed by the body from three different VAP formulations that are added to bouillon. Participants will consume different formulations of VA and have multiple blood collections.


Description:

This study is being conducted to help characterize the absorption of 3 different formulations of VAP (PFH-VAP and BASF-VAP250 vs a positive control) when prepared as broth with an oil dose containing VAP or placebo (referred to as the "study treatments") and consumed by healthy adult women of reproductive age (ages 18 - 49 years). Participants will undergo 3 treatment periods and will be blinded to treatment sequence using a 3-period, 3-treatment crossover design to receive all 3 treatments. All 3 treatment periods will include blood sampling to measure VA levels from pre- through 24 hours post-broth consumption.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 49 Years
Eligibility Inclusion Criteria: - Healthy, nonpregnant women - =18 and <49 years of age - Able and willing to provide informed consent - Body mass index (BMI) between 20 to 30 kg/m2 - Willing and able to undergo study procedures, including: repeated blood sampling, a baseline hemoglobin and pregnancy test, adherence to a low-vitamin A diet at specified times throughout the study, consumption of provided meals (specifically, a breakfast of bouillon, peanut butter, and a bagel or bread), and, except for the Screening visit, foregoing alcohol for at least 2 days before each visit and fasting for =8 hours before each visit Exclusion Criteria: - Currently pregnant - Breastfeeding a child under 1 year of age - Allergic to soy or peanut butter - Current use of smoking tobacco products or any other form of nicotine - Active eating disorder diagnosis - Current diagnosis of acute or chronic illness, including hepatitis, Celiac's disease, Crohn's disease, and cystic fibrosis - Moderate or severe anemia according to World Health Organization guidelines (i.e., hemoglobin =10.9 g/dL) - Unable or unwilling to refrain from consuming alcohol when required - Unable or unwilling to discontinue consumption of foods that are high in vitamin A and of vitamin A supplements when required during the study - Taking prescription oral medication that includes a retinoid, e.g., isotretinoin/ Accutane - Taking proton pump inhibitors. - Unable/unwilling to avoid taking antacids during the fasting period prior to sample collection - Unable/unwilling to fast for periods of at least 10 hours at a time - Status relationship with a member of the study team. - Unable to fulfill study requirements per the judgment of the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Unfortified bouillon plus vitamin A in oil
Participants consume unfortified bouillon with vitamin A oil
Bouillon fortified with vitamin A #1 plus unfortified oil
Participants consume vitamin A #1 fortified bouillon plus unfortified oil
Bouillon fortified with vitamin A #2 plus unfortified oil
Participants consume vitamin A #2 fortified bouillon plus unfortified oil

Locations

Country Name City State
United States University of Wisconsin-Madison Madison Wisconsin
Zambia Tropical Diseases Research Centre Ndola
Zambia Tropical Diseases Research Centre - Field Office Rufunsa

Sponsors (3)

Lead Sponsor Collaborator
University of Wisconsin, Madison Particles for Humanity, PBC, Tropical Diseases Research Centre, Zambia

Countries where clinical trial is conducted

United States,  Zambia, 

Outcome

Type Measure Description Time frame Safety issue
Other Total body vitamin A using retinol isotope dilution The retinol isotope dilution test provides an estimate of total body stores of vitamin A, (umol) Baseline
Other Liver vitamin A concentrations using retinol isotope dilution The retinol isotope dilution test provides an estimate of liver vitamin A concentrations, (umol/g) Baseline
Other C-reactive protein To determine inflammation at each treatment visit, (mg/L) Baseline
Other Serum carotenoids Serum carotenoid concentrations will be measured using high-performance liquid chromatography at baseline for each treatment visit, (nmol/L) Baseline
Primary Serum retinyl ester area-under-the-effect-curve The serum retinyl ester area-under-the-effect-curve (corrected for baseline retinyl ester concentrations) will be calculated for each treatment to determine relative absorption of vitamin A, (nmol/L*h) Baseline to 8 hours
Primary Serum retinyl ester area-under-the-effect-curve The serum retinyl ester area-under-the-effect-curve (corrected for baseline retinyl ester concentrations) will be calculated for each treatment to determine relative absorption of vitamin A, (nmol/L*h) Baseline to 24 hours
Secondary Serum retinol maximum concentration (Cmax) Maximum serum retinol concentration observed, (µmol/L) Baseline to 24 hours
Secondary Serum retinyl ester maximum concentration (Cmax) Maximum serum retinyl ester concentration observed, (nmol/L) Baseline to 24 hours
Secondary Time to maximum serum retinol concentration (Tmax) Time to maximum serum retinol concentration, (h) Baseline to 24 hours
Secondary Time to serum retinyl ester maximum concentration (Tmax) Time to maximum serum retinyl ester concentration, (h) Baseline to 24 hours
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1